Home Other Building Blocks 639089-54-6
639089-54-6,MFCD13185152
Catalog No.:AA003714

639089-54-6 | Tozasertib

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
99+%
in stock  
$9.00   $7.00
- +
5mg
98%(HPLC)
in stock  
$34.00   $24.00
- +
25mg
98%(HPLC)
in stock  
$66.00   $46.00
- +
50mg
99+%
in stock  
$90.00   $63.00
- +
250mg
98%(HPLC)
in stock  
$394.00   $276.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA003714
Chemical Name:
Tozasertib
CAS Number:
639089-54-6
Molecular Formula:
C23H28N8OS
Molecular Weight:
464.5864
MDL Number:
MFCD13185152
SMILES:
CN1CCN(CC1)c1nc(Sc2ccc(cc2)NC(=O)C2CC2)nc(c1)Nc1n[nH]c(c1)C
NSC Number:
745967
Properties
Properties
 
Form:
Solid  
MP:
248-253°C (dec.)  
Storage:
Keep in dry area;-20 ℃;  

Computed Properties
 
Complexity:
650  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
33  
Hydrogen Bond Acceptor Count:
8  
Hydrogen Bond Donor Count:
3  
Rotatable Bond Count:
7  
XLogP3:
3.4  

Literature

Title: The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.

Journal: Journal of medicinal chemistry 20150108

Title: Direct and indirect targeting of MYC to treat acute myeloid leukemia.

Journal: Cancer chemotherapy and pharmacology 20150101

Title: Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.

Journal: Journal of medicinal chemistry 20131024

Title: The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.

Journal: Journal of medicinal chemistry 20130808

Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.

Journal: Bioorganic & medicinal chemistry letters 20130801

Title: A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.

Journal: The Biochemical journal 20130415

Title: Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors.

Journal: Journal of medicinal chemistry 20120913

Title: Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.

Journal: Breast cancer research and treatment 20120901

Title: Activation of Aurora-A is essential for neuronal migration via modulation of microtubule organization.

Journal: The Journal of neuroscience : the official journal of the Society for Neuroscience 20120808

Title: Repression of cancer cell senescence by PKCι.

Journal: Oncogene 20120802

Title: Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor.

Journal: Leukemia research 20120801

Title: Synthesis, biological evaluation, and molecular docking studies of N,1,3-triphenyl-1H-pyrazole-4-carboxamide derivatives as anticancer agents.

Journal: Bioorganic & medicinal chemistry letters 20120601

Title: Acute sensitization of colon cancer cells to inflammatory cytokines by prophase arrest.

Journal: Biochemical pharmacology 20120501

Title: In vitro drug metabolism by C-terminally truncated human flavin-containing monooxygenase 3.

Journal: Biochemical pharmacology 20120215

Title: Targeting aurora kinases: a novel approach to curb the growth & chemoresistance of androgen refractory prostate cancer.

Journal: Current cancer drug targets 20120201

Title: Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen.

Journal: ACS chemical biology 20120120

Title: Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457.

Journal: British journal of haematology 20120101

Title: Vincristine potentiates the anti-proliferative effect of an aurora kinase inhibitor, VE-465, in myeloid leukemia cells.

Journal: Biochemical pharmacology 20111215

Title: Mutants of protein kinase A that mimic the ATP-binding site of Aurora kinase.

Journal: The Biochemical journal 20111115

Title: Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.

Journal: Nature biotechnology 20111101

Title: Comprehensive analysis of kinase inhibitor selectivity.

Journal: Nature biotechnology 20111030

Title: An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B.

Journal: Molecular cancer therapeutics 20111001

Title: Novel series of pyrrolotriazine analogs as highly potent pan-Aurora kinase inhibitors.

Journal: Bioorganic & medicinal chemistry letters 20110915

Title: A novel cell-based, high-content assay for phosphorylation of Lats2 by Aurora A.

Journal: Journal of biomolecular screening 20110901

Title: Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.

Journal: European journal of medicinal chemistry 20110601

Title: Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.

Journal: Cancer research 20110601

Title: VX680 binding in Aurora A: π-π interactions involving the conserved aromatic amino acid of the flexible glycine-rich loop.

Journal: The journal of physical chemistry. A 20110428

Title: Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class.

Journal: Journal of medicinal chemistry 20110414

Title: Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase.

Journal: Journal of medicinal chemistry 20110113

Title: Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cells.

Journal: Journal of translational medicine 20110101

Title: Inhibition of proliferation, viability, migration and invasion of gastric cancer cells by Aurora-A deletion.

Journal: Asian Pacific journal of cancer prevention : APJCP 20110101

Title: Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.

Journal: Cancer research 20101201

Title: Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.

Journal: Chemistry & biology 20101124

Title: Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells.

Journal: Annals of hematology 20101101

Title: Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.

Journal: Oncotarget 20101101

Title: Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53.

Journal: Cell death and differentiation 20100901

Title: A type-II kinase inhibitor capable of inhibiting the T315I 'gatekeeper' mutant of Bcr-Abl.

Journal: Journal of medicinal chemistry 20100812

Title: 3-Cyano-6-(5-methyl-3-pyrazoloamino)pyridines: selective Aurora A kinase inhibitors.

Journal: Bioorganic & medicinal chemistry letters 20100801

Title: Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.

Journal: Journal of medicinal chemistry 20100708

Title: Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase.

Journal: Journal of medicinal chemistry 20100527

Title: Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias.

Journal: Molecular cancer therapeutics 20100501

Title: Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia.

Journal: Biochemical pharmacology 20100301

Title: Inhibition of the aurora kinases suppresses in vitro NT2-D1 cell growth and tumorigenicity.

Journal: The Journal of endocrinology 20100201

Title: In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.

Journal: British journal of haematology 20091201

Title: Overcoming resistance in chronic myelogenous leukemia.

Journal: Leukemia & lymphoma 20091101

Title: The Aurora Kinase in Trypanosoma brucei plays distinctive roles in metaphase-anaphase transition and cytokinetic initiation.

Journal: PLoS pathogens 20090901

Title: The discovery of the potent aurora inhibitor MK-0457 (VX-680).

Journal: Bioorganic & medicinal chemistry letters 20090701

Title: Discovery and exploitation of inhibitor-resistant aurora and polo kinase mutants for the analysis of mitotic networks.

Journal: The Journal of biological chemistry 20090605

Title: Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia.

Journal: Leukemia research 20090601

Title: Discovery and development of aurora kinase inhibitors as anticancer agents.

Journal: Journal of medicinal chemistry 20090514

Title: Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1.

Journal: The Biochemical journal 20090513

Title: Short and long-term tumor cell responses to Aurora kinase inhibitors.

Journal: Experimental cell research 20090415

Title: Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152.

Journal: The pharmacogenomics journal 20090401

Title: Mechanism of MK-0457 efficacy against BCR-ABL positive leukemia cells.

Journal: Biochemical and biophysical research communications 20090320

Title: [Recent advance in the study of novel anti-tumor targets and drugs--aurora kinase and Pin1].

Journal: Yao xue xue bao = Acta pharmaceutica Sinica 20090301

Title: Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.

Journal: Journal of medicinal chemistry 20090122

Title: Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival.

Journal: Molecular cancer 20090101

Title: Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.

Journal: Journal of medicinal chemistry 20081225

Title: Aurora A is essential for early embryonic development and tumor suppression.

Journal: The Journal of biological chemistry 20081114

Title: Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia.

Journal: Blood 20081001

Title: Modulation of kinase-inhibitor interactions by auxiliary protein binding: crystallography studies on Aurora A interactions with VX-680 and with TPX2.

Journal: Protein science : a publication of the Protein Society 20081001

Title: Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells.

Journal: Carcinogenesis 20081001

Title: Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20081001

Title: Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080901

Title: Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.

Journal: Blood 20080801

Title: [Novel medical treatment modalities in hematology].

Journal: Ugeskrift for laeger 20080609

Title: Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies.

Journal: Cancer science 20080601

Title: Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines.

Journal: Endocrine-related cancer 20080601

Title: Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia.

Journal: Blood 20080301

Title: Aurora kinase A inhibitors: identification, SAR exploration and molecular modeling of 6,7-dihydro-4H-pyrazolo-[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-dione scaffold.

Journal: Bioorganic & medicinal chemistry letters 20080301

Title: Spatio-temporal expression patterns of aurora kinases a, B, and C and cytoplasmic polyadenylation-element-binding protein in bovine oocytes during meiotic maturation.

Journal: Biology of reproduction 20080201

Title: A quantitative analysis of kinase inhibitor selectivity.

Journal: Nature biotechnology 20080101

Title: Inhibitors of ABL and the ABL-T315I mutation.

Journal: Current topics in medicinal chemistry 20080101

Title: Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells.

Journal: Journal of translational medicine 20080101

Title: The selectivity of protein kinase inhibitors: a further update.

Journal: The Biochemical journal 20071215

Title: [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].

Journal: Bulletin du cancer 20071001

Title: Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.

Journal: The Journal of clinical investigation 20070904

Title: Hepatic metabolism of MK-0457, a potent aurora kinase inhibitor: interspecies comparison and role of human cytochrome P450 and flavin-containing monooxygenase.

Journal: Drug metabolism and disposition: the biological fate of chemicals 20070901

Title: Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues.

Journal: Endocrine-related cancer 20070901

Title: Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680.

Journal: Cancer letters 20070628

Title: [Novel anti-CML agents beyond imatinib].

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology 20070601

Title: Targeted therapy and the T315I mutation in Philadelphia-positive leukemias.

Journal: Haematologica 20070401

Title: New blood cancer therapies under study.

Journal: JAMA 20070207

Title: With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model.

Journal: Journal of the National Cancer Institute 20070207

Title: MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.

Journal: Blood 20070115

Title: Aurora kinase inhibition downregulates NF-kappaB and sensitises tumour cells to chemotherapeutic agents.

Journal: Biochemical and biophysical research communications 20070105

Title: Analysis of mitotic phosphorylation of borealin.

Journal: BMC cell biology 20070101

Title: Microsphere-based protease assays and screening application for lethal factor and factor Xa.

Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

Title: Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors.

Journal: Journal of medicinal chemistry 20060209

Title: Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

Journal: Cancer research 20060115

Title: Anticancer Drug Discovery and Development - SRI's Seventh Annual Summit.

Journal: IDrugs : the investigational drugs journal 20051001

Title: Dawn of Aurora kinase inhibitors as anticancer drugs.

Journal: Expert opinion on investigational drugs 20040901

Title: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.

Journal: Nature medicine 20040301

Title: Harrington EA, et al. VX-680, a potent and selective smallmolecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004; 10:262-7.

Title: Salah E, et al. Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class.J Med Chem. 2011 Apr 14;54(7):2359-67. Epub 2011 Mar 18.

Title: Arlot-Bonnemains Y, et al. Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. Endocr Relat Cancer. 2008 Jun;15(2):559-68

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 639089-54-6
Tags:639089-54-6 Molecular Formula|639089-54-6 MDL|639089-54-6 SMILES|639089-54-6 Tozasertib